KRON - Kronos Bio Invivoscribe to develop companion diagnostic for leukemia drug entospletinib
- Kronos Bio ( NASDAQ: KRON ) and Invivoscribe, a global provider of oncology diagnostic kits and services, on Tuesday said they had inked a deal to develop a companion diagnostic for use with investigational therapy entospletinib.
- KRON's entospletinib is the company's lead clinical compound.
- It is currently being evaluated in a phase 3 trial for the treatment of newly diagnosed NPM1-mutated acute myeloid leukemia (AML).
- KRON said the diagnostic would screen for the NPM1 mutation, which is present in about one-third of all AML patients.
- KRON stock earlier closed -6% at $4.85.
For further details see:
Kronos Bio, Invivoscribe to develop companion diagnostic for leukemia drug entospletinib